Krishna Yeshwant - 05 Jun 2025 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: VERV
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:00:18 UTC
Prior SEC filing: 28 Jun 2024
Next SEC filing: 28 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Ashe, as Attorney-in-Fact for Krishna Yeshwant

Key filing fact

Krishna Yeshwant filed Form 4 for Verve Therapeutics, Inc. (VERV) on 06 Jun 2025.

Key facts

This page summarizes Krishna Yeshwant's Form 4 filing for Verve Therapeutics, Inc. (VERV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 17:00.

Change

Previous filing in this sequence was filed on 28 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001585001 Primary reporting owner

Yeshwant Krishna

Relationship: Director, 10%+ Owner
Address: C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Krishna Yeshwant
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERV transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +42,200
Change %
Price: $0.000000
Shares after: 42,200
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,200
Exercise price: $5.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.